Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083460 · ClinicalTrials.gov registry record · Phase 1
Study of Combination PS-341 and Thalidomide in Multiple Myeloma
A Phase 1 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT00083460 is a Phase 1 study that has completed, run by University of Arkansas. The registered enrollment target is 86 participants.
The verdict
NCT00083460, a Phase 1 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the toxicity of PS-341 combined with one of four doses of thalidomide in patients with refractory multiple myeloma, and to find the most appropriate doses of PS-341 and thalidomide in the combination.
Interventions
- DRUG Dexamethasone
- DRUG Thalidomide
- DRUG PS-341
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2001-12 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083460
The ClinicalTrials.gov registry entry for NCT00083460 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT00083460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083460 about?
NCT00083460 is a clinical study titled "Study of Combination PS-341 and Thalidomide in Multiple Myeloma". The purpose of this study is to assess the toxicity of PS-341 combined with one of four doses of thalidomide in patients with refractory multiple myeloma, and to find the most appropriate doses of PS-341 and thalidomide in the combination.
What is the current status of trial NCT00083460?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2001-12. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00083460?
The interventions under investigation include: Dexamethasone (DRUG), Thalidomide (DRUG), PS-341 (DRUG).
Who is sponsoring clinical trial NCT00083460?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.